1. Home
  2. NTLA vs CRTO Comparison

NTLA vs CRTO Comparison

Compare NTLA & CRTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTLA
  • CRTO
  • Stock Information
  • Founded
  • NTLA 2014
  • CRTO 2005
  • Country
  • NTLA United States
  • CRTO France
  • Employees
  • NTLA N/A
  • CRTO N/A
  • Industry
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • CRTO Advertising
  • Sector
  • NTLA Health Care
  • CRTO Consumer Discretionary
  • Exchange
  • NTLA Nasdaq
  • CRTO Nasdaq
  • Market Cap
  • NTLA 1.2B
  • CRTO 1.2B
  • IPO Year
  • NTLA 2016
  • CRTO 2013
  • Fundamental
  • Price
  • NTLA $25.74
  • CRTO $20.74
  • Analyst Decision
  • NTLA Buy
  • CRTO Buy
  • Analyst Count
  • NTLA 19
  • CRTO 9
  • Target Price
  • NTLA $30.47
  • CRTO $39.11
  • AVG Volume (30 Days)
  • NTLA 7.7M
  • CRTO 453.7K
  • Earning Date
  • NTLA 11-06-2025
  • CRTO 10-29-2025
  • Dividend Yield
  • NTLA N/A
  • CRTO N/A
  • EPS Growth
  • NTLA N/A
  • CRTO 44.35
  • EPS
  • NTLA N/A
  • CRTO 2.38
  • Revenue
  • NTLA $52,857,000.00
  • CRTO $1,946,032,000.00
  • Revenue This Year
  • NTLA $9.20
  • CRTO N/A
  • Revenue Next Year
  • NTLA N/A
  • CRTO $1.84
  • P/E Ratio
  • NTLA N/A
  • CRTO $8.80
  • Revenue Growth
  • NTLA 14.99
  • CRTO N/A
  • 52 Week Low
  • NTLA $5.90
  • CRTO $20.05
  • 52 Week High
  • NTLA $26.99
  • CRTO $47.27
  • Technical
  • Relative Strength Index (RSI)
  • NTLA 84.32
  • CRTO 33.81
  • Support Level
  • NTLA $19.89
  • CRTO $21.30
  • Resistance Level
  • NTLA $21.49
  • CRTO $22.07
  • Average True Range (ATR)
  • NTLA 1.73
  • CRTO 0.66
  • MACD
  • NTLA 0.71
  • CRTO -0.09
  • Stochastic Oscillator
  • NTLA 86.83
  • CRTO 29.71

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About CRTO Criteo S.A.

Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.

Share on Social Networks: